OPTICARE
Background
Any discontinuation of antiretroviral therapy (ART) can lead to virologic rebound and increased risk of HIV progression. Vulnerable situations represent a major risk to the continuum of care cascade. The OPTICARE program is a multidisciplinary support program response dedicated to patients either lost to follow up or in highly frail situation that offers an individualized care management to optimize care and control of viral replication.
Design
Approximately 400 patients who represented an estimated 10% of vulnerable patients in Pitié-Salpêtrière Hospital were screened for the OPTICARE program. The first 120 eligible patients were enrolled into this retention in care program. Following the enrolment phase, a one year follow up for each patient will be observed. Study methodology includes analysis of a software system enabling monitoring of medical files for each HIV positive patient and questionnaires with stakeholders. The impact of OPTICARE on ART compliance, clinical, immunological and virological outcomes, and patient social and psychologic status will be assessed.
Primary objectives
- Improve number of vulnerable patients entering care (UNAIDS/Second 90% goal)
- Improve drive treatment success (UNAIDS/Third 90% goal) within a one-year period
Collaborators
Prof. Christine Katlama
Dr. Sophie Seang
Setting
Pitié-Salpêtrière Hospital Infectious Disease Department
Location
France
Duration
Sep 2018 – Dec 2022
Category
Retention in Care and Adherence
Key study materials
RELATED STUDIES
ITALY
The RELAPP study is focused upon developing an algorithm for general practitioners in Italy to identify earlier those at risk of HIV.
SPAIN
As part of this study, health workers at the Hospital in non-HIV-Infectious Diseases areas and local NGO are trained to identify Chemsex and HIV-STD signs and symptoms, in order to increase diagnostic screenings of this high-risk population.
USA
This study investigates barriers and facilitators specifically among foreign and US born Spanish and English-speaking Latino MSM.
NP-GBL-HVU-WCNT- 210043 | March 2022
If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the GSK Reporting Tool link https://gsk.public.reportum.com/. By reporting side effects, you can help provide more information on the safety of this medicine.
If you are from outside the UK, you can report adverse events to GSK/ ViiV by selecting your region and market, here.
